The research team confirmed the anti-tumor activity of this ADC both as a monotherapy and in conjunction with sorafenib by integrating an anti-CLDN6 monoclonal antibody with the cytotoxic drug DM1 (CLDN6-DM1). Here, CLDN6 is linked to neoplasm.